Practical management of iron overload

British Journal of Haematology

Volumn 115, Issue 2, 2001, Pages 239-252

  Porter, John B ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Chelation; Desferrioxamine deferiprone; Iron overload; Thalassaemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE;

ANEMIA; ASSAY; BLOOD TRANSFUSION; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; DRUG INFUSION; GASTROINTESTINAL ABSORPTION; HEMOCHROMATOSIS; HUMAN; IRON ABSORPTION; PHLEBOTOMY; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; SURVIVAL RATE; THALASSEMIA; TISSUE DISTRIBUTION;

BONE MARROW TRANSPLANTATION; DEFEROXAMINE; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; PATIENT COMPLIANCE; PHLEBOTOMY; TISSUE DISTRIBUTION;

EID: 0035725868     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.03195.x     Document Type: Review

References (123)

1. Phlebotomy treatment in porphyria cutanea tarda combined with beta-thalassaemia
2. Long term assessment of efficacy and safety of L1, an oral iron chelator in transfusion dependent thalassaemia
3. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyridin-4-one (II) in thalassemia major
4. Results of long-term deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators
5. Pharmacokinetics of the oral iron chelator (L1) in patients with iron overload
6. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome
7. Cardiac iron deposition is not predicted by conventional markers of iron overload in homozygous b-thalassaemia
8. Relationship of myocardial iron overload to right and left function in homozygous β-thalassaemia
9. Needle liver biopsy in thalassaemia: Analyses of diagnostic accuracy and safety in 1184 consecutive biopsies
10. Treatment of iron overload in the "ex-thalassemic". Report from the phlebotomy program
11. Hepatic iron concentration and total body iron stores in thalassemia major
12. A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload
13. Ocular changes in patients undergoing long term desferrioxamine treatment
14. Beta- thalassemia trait might increase the severity of haemochromatosis in subjects with the C282Y mutation in the HFE gene
15. Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey
16. Myocardial iron grading by endomyocardial biopsy. A clinico-pathologic study on iron overloaded patients
17. Long term chelation therapy in thalassaemia: Effect on liver iron concentration, liver histology and clinical progress
18. Management of hemochromatosis
19. Cerebral and ocular toxicity induced by desferrioxamine
20. Evaluation of a new method of administration of the iron chelating agent deferoxamine
21. Rapid desensitisation for desferrioxamine analylactoid reaction
22. Non-transferrin-bound iron induced by myeloablative chemotherapy
23. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major
24. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major
25. Effect of age at start of iron chelation therapy on gonadal function in β-thalassemia major
26. Serum ferritin concentration in sickle crisis
27. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda
28. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis
29. Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalassaemia major and iron overload
30. Prospective study of the hypothalamic-pituitary axis in thalassaemic patients who develop secondary amenorrhoea
31. Desferrioxarnine ototoxicity in an adult transfusion dependent population
32. Thrombotic risk of children with thalassemia
33. Rapid removal of excessive iron with daily high dose intravenous chelation therapy
34. Safety profile of the oral iron chelator deferiprone: A multicentre study
35. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease
36. Four new mutations in the erythroid-specific 5-aminotevulinate synthase (ALAS2) gene causing X-linked sideroblastic anemia. Increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis
37. Ocular toxicity of high-dose intravenous desferrioxamine
38. Survival in homozygous P-Thalassaemia: A single centre study
39. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia
40. Endocrine complications in thalassaemia major
41. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine
42. Desferrioxamine-induced growth retardation in patients with thalassaemia major
43. Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting
44. Acute aphasia and loss of vision with desferrioxamine overdose
45. Iron metabolism in thalassemia intermedia
46. Treatment of Cooleys anaemia
47. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload
48. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions
49. Results of long term chelation therapy
50. Yersinia sepsis in patients with iron overload treated with desferrioxamine
51. Iron overload, causes and consequences
52. Non-invasive prediction of fibrosis in C282Y homozygous hemochromatosis
53. Mechanism of desferrioxamine induced iron excretion in thalassaemia
54. Prospects for oral iron chelation
55. Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamon anaemia during oral chelator trial
56. Long-term deferiprone in 51 transfusion-dependent iron overloaded patients
57. In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine haemopoeisis
58. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload
59. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload
60. Effective chelation of iron in f3 thalassaemia with the oral chelator 1,2,dimethyl-3-hydroxypyridin-4-one
61. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one
62. Deferiprone for thalassaemia
63. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major
64. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemia patients
65. Iron balance in thalassemia patients treated with deferiprone
66. The influence of hemochromatosis mutations on iron overload of thalassemia major
67. Desferrioxamine to improve cardiac function in iron overloaded patients with thalassaemia major
68. Fatal systemic lupus erythematosus in patient taking oral iron chelator LI
69. Autoantibodies in thalassaemia major: Relationship with oral iron chelator L1
70. Rapid desenstitisation for desferrioxamine anaphylactic reaction
71. Total management of thalassaemia major
72. Survival in beta-thalassaemia major in the UK: Data from the UK thalassaemia register
73. Long term desferrioxamine therapy in thalassaemia
74. Vitamin C and Iron
75. Iron burden in sickle cell anemia
76. Transfusion-induced decrease in spleen size in thalassemia major: Documentation by radioisotopic scan
77. Iron-chelating therapy and the treatment of thalassemia
78. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
79. Visual and auditory neurotoxicity in patients receiving subcutaneous desferrioxamine infusions
80. Comparison of oral iron chelator L1 and desferrioxamine in iron loaded patients
81. Growth failure and bony changes induced by deferoxamine
82. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia
83. Survival in medically treated patients with homozygous beta-thalassemia
84. Iron-chelation therapy with oral deferiprone for patients with thalassemia major
85. High dose desferrioxamine as a cause of growth failure in thalassaemic patients
86. No progression of liver fibrosis in thalassaemia major during deferiprone or desferrioxamine iron chelation
87. Iron absorption in iron-loading anaemias
88. Iron absorption and loading in beta-thalassaemia intermedia
89. Intensive iron-chelation with desferrioxamine in iron-loading anaemias
90. Prevention of iron loading in transfusion dependent thalassaemia
91. Ferrioxamine excretion in iron loaded man
92. Hepatocyte iron kinetics in the rat explored with an iron chelator
93. Oral iron chelation therapy for thalassaemia: An uncertain scene
94. Deferiprone for thalassaemia
95. The effect of erythroid hyperplasia on iron balance
96. Transfusion and exchange transfusion in sickle cell anaemia, with particular reference to iron metabolism
97. Preliminary findings with single dose evaluation of a new depot formulation of deferoxamine (ICL 749B) for transfusion-dependent beta-thalassemia
98. Evaluation of chelators for clinical use
99. A risk-benefit assessment of iron-chelation therapy
100. Desferrioxamine ototoxicity: Evaluation of risk factors in thalassaemic patients and guidelines for safe dosage
101. Animal toxicology of iron chelator L1
102. Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and non-overloaded mice
103. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with desferrioxamine therapy
104. A trial to investigate the relationship between desferrioxamine phartnacokinetics and metabolism and desferrioxamine-related toxicity
105. Continuous subcutaneous administration of deferoxamine in patients with iron overload
106. Reassessment of the use of deferoxamine B in iron overload
107. Effects of iron and desferrioxamine on infections with Yersinia Enterocolitica
108. Liver iron overload and desferrioxamine treatment of porphyria cutanea tarda
109. Iron excretion in thalassaemia major after administration of chelating agents
110. Chelator-induced iron excretion in iron-overloaded marmosets
111. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients
112. Variability in hepatic iron concentration measurement from needle-biopsy specimens
113. Absence of deferiprone-induced hepatic fibrosis. A multi-center study
114. Determinants of iron status and bilirubin levels in congenital dyserythropoietic anaemia type I
115. Prevention of cardiac disease by subcutaneous desferrioxamine in patients with thalassaemia major
116. Combined therapy with deferiprone and desferrioxamine
117. Serum ferritin
118. Pathogenesis and management of haemohromatosis
119. Iron status in red cell pyruvate kinase deficiency: Study of Italian cases
120. Chelation and mobilization of cellular iron by different classes of chelators
121. Survival and causes of death in thalassaemia major